Mostrar el registro sencillo

dc.contributor.authorGea, Ana
dc.contributor.authorFernández, Tatiana
dc.contributor.authorFernández Luis, Sara
dc.contributor.authorDomínguez García, Juan José
dc.contributor.authorFrancés, Irene
dc.contributor.authorTobalina, Ana
dc.contributor.authorCantera, Rodrigo
dc.contributor.authorBannatyne, Julia
dc.contributor.authorGorostidi, Irene
dc.contributor.authorOviedo, María
dc.contributor.authorCerezo, Juan M.
dc.contributor.authorGarcía, Raquel
dc.contributor.authorInsunza Gaminde, Andrés
dc.contributor.authorMontes Gaisán, Carmen María
dc.contributor.authorBermúdez, Aránzazu
dc.contributor.authorMontes Moreno, Santiago 
dc.contributor.authorBriz, Montserrat
dc.contributor.authorOcio San Miguel, Enrique María 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-07-09T11:27:11Z
dc.date.issued2025-04
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.urihttps://hdl.handle.net/10902/36641
dc.description.abstractMultiple myeloma (MM) diagnosis requires 10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality. In the remaining 33 patients, BMB diagnosed MM, while BMA detected < 10% PC, being symptomatic in 16 patients and smouldering (SMM) in 17. Without an initial BMB, 11% would have been misdiagnosed; and 12% of symptomatic patients would require a second BMA or BMB for strict diagnosis according to current criteria.es_ES
dc.format.extent4 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceClinical Lymphoma, Myeloma & Leukemia, 2025, 25(4), e210-e213es_ES
dc.subject.otherBone marrowes_ES
dc.subject.otherAspiratees_ES
dc.subject.otherMultiple myelomaes_ES
dc.titleIs bone marrow trephine biopsy necessary in multiple myeloma patients at diagnosis?es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.clml.2024.12.004es_ES
dc.rights.accessRightsembargoedAccesses_ES
dc.identifier.DOI10.1016/j.clml.2024.12.004
dc.type.versionacceptedVersiones_ES
dc.embargo.lift2026-05-01
dc.date.embargoEndDate2026-05-01


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license